Amgen stock gains as Wells Fargo lifts price target after strong Q2 2026 results

Amgen stock is trading near its 52-week high in early September 2026, after strong Q2 2026 earnings and a new Wells Fargo price target support sentiment around the biotech group.

Amgen stock (ISIN US0311621009) is trading close to a fresh 52-week high in early September 2026, with recent quotes around 444.12 USD as of September 3, 2026 on Nasdaq according to market data summarized by MarketBeat and MarketScreener. The shares stand just below a 52-week high of 447.03 USD, underlining a strong recovery from a 52-week low of 269.77 USD over the past year and a gain of more than 60% in that period as reported by Investing.com.

Wells Fargo raises price target on Amgen

According to an analyst note reported by Investing.com on September 4, 2026, Wells Fargo has raised its price target for Amgen stock to 435 USD from 400 USD while maintaining an Equal Weight rating. At a recent trading level of 444.12 USD, the new target sits slightly below the market price, indicating that the bank sees limited additional upside in the near term despite the strong run in the shares.

The same Investing.com overview states that Amgen stock has delivered about a 63% return over the past 12 months, with the current quote near the 52-week high of 447.03 USD. This places the stock within only a few dollars of its yearly peak and far above the 52-week low of 269.77 USD recorded earlier in the period, a performance that stands out among large-cap healthcare names.

Q2 2026 earnings beat and guidance support the valuation

The rally in Amgen stock is supported by robust fundamentals. As detailed by a MarketBeat analysis summarizing the latest quarterly figures, Amgen reported second quarter 2026 revenue of 10.05 billion USD, beating analyst expectations of 9.43 billion USD. That corresponds to a year-over-year revenue increase of 9.5% compared with the same quarter of the prior year.

On the earnings side, MarketBeat highlights that adjusted earnings per share (EPS) reached 6.29 USD in Q2 2026, above the consensus estimate of 5.62 USD and up from 6.02 USD in the year-ago quarter. This means Amgen outperformed expectations by 0.67 USD per share and expanded EPS by around 4.5% year over year, while delivering a net margin of 22.95% and a return on equity of 124.14% in the latest quarter.

For the full year 2026, Amgen has set guidance for EPS in a range of 22.30 to 23.50 USD according to the same MarketBeat summary. Equity research analysts cited there expect the company to post 22.97 USD in EPS for the current fiscal year 2026, placing consensus slightly above the midpoint of management’s guidance range and signaling confidence that the company can deliver on its outlook.

Dividend and valuation perspective for investors

Alongside earnings, Amgen continues to return cash to shareholders. MarketBeat notes that the company declared a quarterly dividend of 2.52 USD per share, which translates into an annualized dividend of 10.08 USD and a yield of about 2.3% at recent prices around the mid-440 USD area. The ex-dividend date for this payout was August 21, 2026, with the dividend scheduled to be paid on September 11, 2026, offering income-oriented investors a tangible return component on top of capital gains.

From a valuation standpoint, the same MarketBeat data show that analysts maintain an overall consensus rating of Hold on Amgen, with a consensus price target of 380.43 USD. With the stock currently trading around 444.12 USD and the average target below that level, the market price is clearly above the typical analyst target while still within sight of individual higher targets such as 435 USD from Wells Fargo and increases reported by other houses like Oppenheimer to 450 USD and TD Cowen to 452 USD in the MarketBeat coverage.

For investors, the combination of double-digit billion revenue in Q2 2026, an EPS beat of 0.67 USD over consensus, and a dividend yield of about 2.3% underpins the share price near the 52-week high. At the same time, the gap between the current quote and the average analyst target suggests that expectations embedded in Amgen stock have moved ahead of the more cautious consensus view.

Representative Amgen product: Repatha and cardiovascular portfolio

Amgen’s investment story is closely tied to its portfolio of biologic medicines and cardiovascular therapies, including the cholesterol-lowering drug Repatha. Repatha is one of the company’s key products in the PCSK9 inhibitor class, designed to reduce low-density lipoprotein (LDL) cholesterol in high-risk patients when statins alone are not sufficient. While the latest Q2 2026 figures summarized by MarketBeat do not break out Repatha-specific numbers, the double-digit billion revenue total and 9.5% year-over-year growth indicate that major franchises such as Repatha and other innovative therapies continue to contribute meaningfully to Amgen’s top line and support the 2026 EPS guidance of 22.30 to 23.50 USD.

Amgen stock near 52-week high on Nasdaq

According to the price performance section in several MarketBeat alerts on September 4, 2026, Amgen shares opened at 444.12 USD, with a 52-week low of 269.77 USD and a 52-week high of 447.03 USD. This places the stock just 0.7% below its yearly peak, while the distance from the low exceeds 60%, illustrating how strongly the shares have rebounded over the past year as fundamentals and guidance improved.

For investors watching the Nasdaq listing, the current price level around 444 USD as of September 3, 2026, the 2.3% dividend yield based on a 10.08 USD annualized dividend, and the Q2 2026 revenue of 10.05 billion USD together frame Amgen as a large-cap biotech that combines growth and income. The fact that Wells Fargo has raised its price target to 435 USD while maintaining an Equal Weight rating, and that consensus targets compiled by MarketBeat average 380.43 USD, shows that professional assessments are more cautious than the market’s recent enthusiasm, a divergence that investors may factor into their own view of the risk-return profile.

Amgen stock facts

• Company: Amgen Inc.
• ISIN: US0311621009
• Ticker: AMGN
• Trading venue: NASDAQ
• Price (as of September 3, 2026): 444.12 USD
• Market capitalization: Not specified (as of latest available data)
• Sector / Industry: Biotechnology / Pharmaceuticals
• Index membership: S&P 500